[管理者用] 最新ニュース(タブ)
サブ-ナビゲーション
information
News
Corporate Guide
Business
Investor Relations
Sustainability
Contact Us
[管理者用] 最新ニュース(タブ)
What’s new
Press Release
Investor Relations
Information
2026/04/28
Notice of the Extraordinary Shareholders’ Meeting
(544KB)
2026/04/27
Notice Regarding Cancellation of Treasury Stock
(250KB)
2026/04/27
Notice about Share Consolidation, Abolition of the Provision on Share Units and Partial Amendment of the Articles of Incorporation
(536KB)
2026/04/07
Announcement of Results of the Tender Offer by Takara Holdings, the Parent Company of the Company, for the Common Stock of the Company
(348KB)
2026/03/26
Notice Regarding Setting of Record Date for Convocation of Extraordinary General Shareholders’ Meeting
(194KB)
Read More
2026/02/06
Waskyra™, a Gene Therapy Manufactured Using RetroNectin®, Receives U.S. and EU Marketing Authorization Approvals
2025/09/16
Completion of Clinical Trial Notification Process in Japan for Confirmatory Study of NY-ESO-1・siTCR™ Gene Therapy
2025/09/12
Announcement of “Takara Bio Group Long-Term Vision 2050”
2025/06/04
Redesign of the Regulatory Strategy for NY-ESO-1・siTCR™ Gene Therapy in Japan
2024/06/27
Takara Bio announces the business partnership with Gap Junction Therapeutics to develop AAV gene therapy for hereditary hearing loss
Read More
2026/04/28
Notice of the Extraordinary Shareholders’ Meeting
(544KB)
2026/04/27
Notice Regarding Cancellation of Treasury Stock
(250KB)
2026/04/27
Notice about Share Consolidation, Abolition of the Provision on Share Units and Partial Amendment of the Articles of Incorporation
(536KB)
2026/04/07
Announcement of Results of the Tender Offer by Takara Holdings, the Parent Company of the Company, for the Common Stock of the Company
(348KB)
2026/03/26
Notice Regarding Setting of Record Date for Convocation of Extraordinary General Shareholders’ Meeting
(194KB)
Read More
2024/05/02
Takara Bio to Present Advances in Gene and Cell Research at ASGCT 2024
Read More
PAGETOP
PAGETOP
CLOSE
MENU
サイト内検索
menu
JA
EN
contact
gnavi-box